syahrir maulana Large-cap companies are typically more mature, resulting in lower volatility during turbulent market conditions as investors gravitate towards quality and adopt a more risk-averse stance. Over the last year, many investors have gravitated to the Mega-Cap stocks on fears of rising interest rates, inflation concerns, and a potential recession. Historically, March has been a great time to buy the dip in small-cap stocks, as showcased in the iShares Core S&P Small-Cap ETF (IJR) seasonality c ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about ANI Pharmaceuticals (ANIP) .ANI currently has an average brokerage recommendation (ABR) of 1.25 ...

Have you been paying attention to shares of ANI Pharmaceuticals (ANIP) ? Shares have been on the move with the stock up 19.8% over the past month. The stock hit a new 52-week high of $70.5 in the previous session. ANI Pharmaceuticals has gained 22.7% since the start of the year compared to the 6.2% move for the Zacks Medical sector and the 1.3% return for the Zacks Medical - Biomedical and Genetics industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it ...

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2023 Earnings Conference Call February 29, 2024 8:30 AM ET Company Participants Judy DiClemente - Insight Communications, IR Nikhil Lalwani - President and CEO Stephen Carey - CFO Conference Call Participants Gary Nachman - Raymond James Operator Good day everyone, and welcome to today's ANI Pharmaceuticals Inc. Fourth Quarter 2023 Earnings Results Call. At this time, all participants are in a listen-only mode. Later you will have the opportunity to ask questions d ...

For the quarter ended December 2023, ANI Pharmaceuticals (ANIP) reported revenue of $131.65 million, up 39.7% over the same period last year. EPS came in at $1.00, compared to $0.76 in the year-ago quarter.The reported revenue represents a surprise of +7.02% over the Zacks Consensus Estimate of $123.02 million. With the consensus EPS estimate being $0.80, the EPS surprise was +25.00%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...

Generated quarterly net revenues of $131.7 million, representing year-over-year growth of 39.7%, net income to common shareholders of $0.7 million, GAAP diluted earnings per share of $0.04Delivered adjusted non-GAAP EBITDA of $30.2 million, and adjusted non-GAAP diluted earnings per share of $1.00Rare Disease business delivered Q4 net revenues of $41.7 million, representing quarter-over-quarter growth of 40.4% and year-over-year growth of 137.3%Generated $119.0 million in cash from operating activities duri ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______. Commission file number 001-31812 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 58-2301143 (State or other j ...

Wall Street analysts forecast that ANI Pharmaceuticals (ANIP) will report quarterly earnings of $0.80 per share in its upcoming release, pointing to a year-over-year increase of 5.3%. It is anticipated that revenues will amount to $123.02 million, exhibiting an increase of 30.6% compared to the year-ago quarter.Over the last 30 days, there has been an upward revision of 16.9% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsi ...

The market expects ANI Pharmaceuticals (ANIP) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to b ...